INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). Additionally, a retrospective cohort study... Additionally, a retrospective cohort study investigated the effectiveness and safety of specific hyperimmune equine serum for severe hospitalized COVID-19 patients (NCT04954235).
- Mechanism
- Curator reviewed
INM005 is a purified Fab fraction of equine hyperimmune serum. The candidate was generated by using the SARS-CoV2 receptor binding domain as an antigenic stimulant, and is thought to exert its effect by neturalizing the virus' interaction with a receptor. As of August 2020, the safety and pharmacokinetics of INMO005 is being tested in a randomized, controlled study (NCT04494984).
- Also known as
- INM-005 (PURIFIED FAB'2 FRACTION OF EQUINE HYPERIMMUNE SERUM GENERATED FROM ANTIGENIC STIMULATION WITH THE SARS-COV2 RBD PROTEIN)
- Code names
- INM-005
Resolves to
What you can answer from here — as of April 25, 2026
Which companies are running trials of INM005, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account